...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children
【24h】

Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children

机译:儿童乳胶舌下免疫疗法的成分分辨免疫学修饰,功效和耐受性

获取原文
获取原文并翻译 | 示例

摘要

Background: As the frequency of natural rubber latex (NRL) allergy has increased, attempts have been made to diminish exposure in high-risk patients. Despite some good results, complete NRL avoidance was not possible, so latex immunotherapy was developed. Objective: To examine variations in immunologic parameters, clinical efficacy, and safety of NRL sublingual immunotherapy (SLIT). Methods: This prospective, observational, open, case-control study included 23 patients (18 patients receiving NRL SLIT and 5 controls). Skin prick, conjunctival provocation, and in-use tests with NRL, specific IgE and specific IgG4 to NRL, specific IgE to recombinant NRL allergens, and basophil activation test (BAT) with whole latex, natural, and recombinant allergens were performed before immunotherapy (T0) and at 6 (T1) and 12 months (T2) of treatment. Results: Patients were sensitized to Hev b 5, Hev b 6.01, and Hev b 6.02 proteins, optimal for SLIT. Changes in specific IgE were not significant. Increases in specific IgG4 between T1 and T2 were larger in the active group. BAT determinations showed significant decreases in recombinant Hev b 6.01 and natural Hev b 6.02 in the active group at T1 but not at T2. Both groups had new sensitizations at T1 but not at T2. The active group had significant increases in the response threshold in the in vivo tests at T1 and T2. Adverse effects were limited to local reactions. Conclusion: NRL SLIT is effective and safe in children with latex allergy. Our results suggest that specific IgE determinations and BAT measurements to natural and recombinant latex allergens may allow obtaining an allergen-based diagnosis to help determine specific immunotherapy.
机译:背景:随着天然橡胶胶乳(NRL)过敏频率的增加,已尝试减少高风险患者的暴露。尽管取得了一些良好的结果,但仍无法完全避免使用NRL,因此开发了乳胶免疫疗法。目的:研究NRL舌下免疫疗法(SLIT)的免疫学参数,临床疗效和安全性的差异。方法:这项前瞻性,观察性,开放性,病例对照研究包括23例患者(18例接受NRL SLIT的患者和5例对照)。在免疫疗法之前进行了皮肤刺,结膜刺激和NRL使用中的试验,针对NRL的特异性IgE和特异性IgG4,针对重组NRL过敏原的特异性IgE以及对全乳胶,天然和重组过敏原的嗜碱性粒细胞活化试验(BAT)( T0),治疗的6(T1)和12个月(T2)。结果:患者对Hev b 5,Hev b 6.01和Hev b 6.02蛋白敏感,最适合SLIT。特异性IgE的变化不明显。在活动组中,T1和T2之间特异性IgG4的增加更大。 BAT测定显示,活性组中的重组Hev b 6.01和天然Hev b 6.02在T1处显着降低,而在T2处则没有。两组在T1时都有新的致敏作用,但在T2时没有。在T1和T2的体内测试中,活性组的反应阈值显着增加。不良反应仅限于局部反应。结论:NRL SLIT治疗乳胶过敏儿童安全有效。我们的结果表明,针对天然和重组乳胶过敏原的特异性IgE测定和BAT测量可能允许获得基于过敏原的诊断,以帮助确定特异性免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号